Creato da XagenaMedicina il 15/10/2009

Xagena Medicina

Discussione di argomenti medico-farmacologici

 

« Neurology NewsMalattie rare & Biomedicina News »

Oncology News

Pazopanib
www.oncologyonline.net/?q=Pazopanib
A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from ...
 

Afinitor
www.oncologyonline.net/?q=Afinitor
Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have ...
 

Nivolumab
www.oncologyonline.net/?q=Nivolumab
Bristol-Myers Squibb has announced long-term follow-up results ( median follow up of 20.3 months ) from the lung cancer cohort ( n=129 ) of the expanded ...
 

Epoetin alfa
www.oncologyonline.net/?q=Epoetin%20alfa
A study suggests that Aranesp ( Darbepoetin alfa ) administered every three weeks with intravenous ( IV ) iron has the potential to further enhance the ...

Ramucirumab
www.oncologyonline.net/?q=Ramucirumab
The results from the Phase III REGARD trial of Ramucirumab as a single agent in patients with advanced gastric cancer who have had disease progression after ...

La URL per il Trackback di questo messaggio è:
https://blog.libero.it/XagenaMedicina/trackback.php?msg=12858242

I blog che hanno inviato un Trackback a questo messaggio:
Nessun trackback

 
Commenti al Post:
Nessun commento
 
RSS (Really simple syndication) Feed Atom
 

AREA PERSONALE

 

ARCHIVIO MESSAGGI

 
 << Luglio 2024 >> 
 
LuMaMeGiVeSaDo
 
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31        
 
 

CERCA IN QUESTO BLOG

  Trova
 

FACEBOOK

 
 

FACEBOOK

 
 
Citazioni nei Blog Amici: 54
 

ULTIME VISITE AL BLOG

a_solitary_manprefazione09Alfa_Beta416161m12ps12acer.250Desert.69XagenaMedicinatiberis1santiago.gamboadony686marabertowiltuocognatino1cassetta2ilmondodiisidejonas21
 

CHI PUò SCRIVERE SUL BLOG

Solo l'autore può pubblicare messaggi in questo Blog e tutti gli utenti registrati possono pubblicare commenti.
I messaggi e i commenti sono moderati dall'autore del blog, verranno verificati e pubblicati a sua discrezione.
 
RSS (Really simple syndication) Feed Atom
 
 
 
 

© Italiaonline S.p.A. 2024Direzione e coordinamento di Libero Acquisition S.á r.l.P. IVA 03970540963